Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Matt KaeberleinAudio: American English

Podcast: topical rapamycin for aging skin and the path to FDA approval

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

At a glance

Automatic summary · not editorially reviewed

In this podcast description, host Matt Kaeberlein talks with Chris Sell and Christina Chung of Hayflick Therapeutics about rapamycin, mTOR and cellular senescence in skin, and about their move from basic science to a controlled human study of topical rapamycin. [1]

  1. The description says early experiments showed rapamycin can extend the replicative lifespan of human cells. [1]

  2. The description says the guests discuss what happens when mTOR remains active in senescent cells. [1]

  3. The description says the guests moved from basic science to a controlled human study of topical rapamycin. [1]

Rapamycin, mTOR and cell lifespan in the lab

The description says the episode covers early experiments showing that rapamycin can extend the replicative lifespan of human cells. It also says the guests discuss what happens when mTOR remains active in senescent cells. Chris Sell is described as having spent decades studying cellular senescence, IGF signaling, mTOR and rapamycin. These are described as laboratory findings; the description does not report results in people from these experiments. [1]

Topical rapamycin study in aging human skin

The description says the guests moved from basic science to a controlled human study of topical rapamycin. The question posed is whether targeting mTOR with topical rapamycin could improve the function and appearance of aging human skin. Christina Chung is described as a dermatologist whose work with transplant patients gave her a different perspective on rapamycin and its effects on skin biology. The description does not give the study's size, duration, comparison group or results. [1]

Hype in aesthetics and the FDA approval route

The description says the episode contrasts scientifically rigorous skin rejuvenation with the large amount of hype in the aesthetics industry. It also says Hayflick is pursuing the more difficult path of FDA approval, and that the conversation addresses how interventions affecting fundamental aging mechanisms can be translated into therapies that can be tested, approved and used in people. The host discloses serving on the company's Scientific Advisory Board. [1]

Context & limits

This is only the video description; the video and transcript were not reviewed. The description gives no study size, duration, comparison group or results, and no human outcomes are reported. The host discloses a role on the company's Scientific Advisory Board.

Based on the creator’s description; the full video and transcript were not analyzed.

[1] Can Rapamycin Reverse Skin Aging? The Science of Skin Rejuvenation
Quoted passages in the original language
extend the replicative lifespan of human cells
when mTOR remains active in senescent cells
a controlled human study of topical rapamycin

About this video

Creator description · original textText language: American English

Subscribe to our channel: https://www.youtube.com/@mkaeberlein Can rapamycin reverse skin aging? In this episode of Longevity Science, I sit down with Dr. Chris Sell and Dr. Christina Chung, co-founders of Hayflick Therapeutics, to explore the science behind using rapamycin to target aging in the skin. Chris has spent decades studying cellular senescence, IGF signaling, mTOR, and rapamycin. Christina is a dermatologist whose work with transplant patients gave her a very different perspective on rapamycin and its effects on skin biology. Their paths eventually converged around a fascinating question: could targeting mTOR with topical rapamycin actually improve the function and appearance of aging human skin? We discuss the early experiments showing that rapamycin can extend the replicative lifespan of human cells, what happens when mTOR remains active in senescent cells, and how Chris and Christina moved from basic science to a controlled human study of topical rapamycin. We also talk about why skin may be an underappreciated organ in geroscience, the difference between scientifically rigorous skin rejuvenation and the enormous amount of hype in the aesthetics industry, and why Hayflick is pursuing the much more difficult path of FDA approval. More broadly, this conversation gets at one of the biggest challenges facing geroscience: how do we translate interventions that affect fundamental mechanisms of aging into therapies that can actually be tested, approved, and used in people? Disclosure: I serve on the Scientific Advisory Board (SAB) of Hayflick Therapeutics. This relationship is disclosed so viewers can appropriately consider any potential conflict of interest. The discussion reflects my own views and is intended for scientific and educational purposes. Topics include: rapamycin and mTOR, cellular senescence, the Hayflick limit, skin aging and rejuvenation, topical rapamycin, transplant dermatology, FDA drug development, and translating geroscience into human medicine. DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find me: Instagram: https://www.instagram.com/mkaeberlein/ LinkedIn: https://www.linkedin.com/in/mkaeberlein/ Twitter: https://twitter.com/mkaeberlein Facebook: https://www.facebook.com/matt.kaeberlein/ --- Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this channel I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Matt Kaeberlein · 60 min · Source published: 2026-10-12

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…